VXRT
NASDAQVaxart Inc
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News · 26 weeks87-69%
2026-03-012026-08-23
Mix4290d
- SEC Filings22(52%)
- Other13(31%)
- Insider5(12%)
- Leadership1(2%)
- Earnings1(2%)
Latest news
25 items- SECVaxart Inc filed SEC Form 8-K: Other Events8-K - Vaxart, Inc. (0000072444) (Filer)
- SECSEC Form 10-Q filed by Vaxart Inc10-Q - Vaxart, Inc. (0000072444) (Filer)
- SECSEC Form 8-K filed by Vaxart Inc8-K - Vaxart, Inc. (0000072444) (Filer)
- PRVaxart Provides Business Update and Reports Second Quarter 2026 Financial ResultsReported topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial; Topline data from 400-person sentinel safety cohort and approximately 5,000 participants in main cohort anticipated in first half of 2027 Cash, cash equivalents, and investments of $64.0 million as of June 30, 2026; Runway into second quarter of 2027 Live stockholder fireside chat scheduled for August 7, 2026 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced its business
- PRVaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ETCompany to report second quarter 2026 financial results on August 6 SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of the Company’s senior management team will participate in a virtual fireside chat on Friday, August 7, 2026, at 4:30 p.m. ET / 1:30 p.m. PT as part of its regular series to answer frequently asked questions from its stockholders. The Company plans to report financial results for the second quarter ended June 30, 2026, after the market close on Thursday, August 6, 2026. The
- SECVaxart Inc filed SEC Form 8-K: Other Events8-K - Vaxart, Inc. (0000072444) (Filer)
- PRVaxart to Participate in BTIG Biotechnology Conference 2026SOUTH SAN FRANCISCO, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of its management team will participate in the BTIG Virtual Biotechnology Conference taking place virtually July 28, 2026. BTIG Biotechnology Conference 2026Date: Tuesday, July 28, 2026Format: 1x1 MeetingsLocation: VirtualInstitutional Investors interested in meeting with Vaxart management should contact their BTIG representative. About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines base
- INSIDERDirector Finney Kevin was granted 39,400 shares, increasing direct ownership by 19% to 244,171 units (SEC Form 4)4 - Vaxart, Inc. (0000072444) (Issuer)
- INSIDERDirector Breitmeyer James B was granted 8,315 shares, increasing direct ownership by 11% to 87,115 units (SEC Form 4)4 - Vaxart, Inc. (0000072444) (Issuer)
- INSIDERDirector Heron Elaine J was granted 39,400 shares, increasing direct ownership by 41% to 135,966 units (SEC Form 4)4 - Vaxart, Inc. (0000072444) (Issuer)
- INSIDERDirector Watson W. Mark was granted 39,400 shares, increasing direct ownership by 29% to 173,525 units (SEC Form 4)4 - Vaxart, Inc. (0000072444) (Issuer)
- INSIDERDirector Wheadon David E. was granted 39,400 shares, increasing direct ownership by 84% to 86,150 units (SEC Form 4)4 - Vaxart, Inc. (0000072444) (Issuer)
- SECVaxart Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Vaxart, Inc. (0000072444) (Filer)
- PRVaxart Announces Results of Annual Meeting of StockholdersSOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, yesterday held its Annual Meeting of Stockholders (the "Annual Meeting") in a virtual-only format. Results from the Annual Meeting indicate that two proposals were approved and one proposal was rejected by Vaxart stockholders. Stockholders voted in favor of the following proposals in alignment with the Board of Directors’ recommendations: Election of six director nominees to serve until the 2027 Annual Meeting of StockholdersRatification
- SECVaxart Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Vaxart, Inc. (0000072444) (Filer)
- PRVaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 VaccineNo vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events related to the vaccine reported SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) today announced topline data from the approximately 400-participant sentinel safety cohort of its Phase 2b clinical trial evaluating the Company’s oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator. Participants in this safety cohort received Vaxart’s oral pill vaccine (201 participants dosed) or an approved mRNA vaccine (199 participants dosed) targeting the XBB strain of SARS-CoV-2, the virus that causes COVID-19. No vaccine-related serious adve
- SECSEC Form DEFA14A filed by Vaxart IncDEFA14A - Vaxart, Inc. (0000072444) (Filer)
- SECSEC Form DEFA14A filed by Vaxart IncDEFA14A - Vaxart, Inc. (0000072444) (Filer)
- SECVaxart Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Vaxart, Inc. (0000072444) (Filer)
- SECSEC Form DEFA14A filed by Vaxart IncDEFA14A - Vaxart, Inc. (0000072444) (Filer)
- PRVaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance EnhancementsCompany to Appoint Mutually Agreed Upon Independent Director; Forms Stockholder Engagement and Clinical and Regulatory Affairs Committees Stockholder Group Withdraws Director Nominations SOUTH SAN FRANCISCO, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced a resolution to the proxy contest in connection with the Company’s 2026 Annual Meeting of Stockholders, reflecting a commitment to value creation, strong corporate governance and constructive engagement with stockholders. Vaxart will initiate
- SECSEC Form DEFA14A filed by Vaxart IncDEFA14A - Vaxart, Inc. (0000072444) (Filer)
- SECSEC Form DEFA14A filed by Vaxart IncDEFA14A - Vaxart, Inc. (0000072444) (Filer)
- SECVaxart Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Vaxart, Inc. (0000072444) (Filer)
- SECSEC Form DEFA14A filed by Vaxart IncDEFA14A - Vaxart, Inc. (0000072444) (Filer)
VXRT FAQ
6 questionsWhat does Vaxart Inc do?
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the...Where does VXRT stock trade?
Vaxart Inc (VXRT) is listed on NASDAQ.What sector and industry is VXRT in?
Vaxart Inc operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about VXRT?
Vaxart Inc has had 6 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $400.00 price target on 2024-08-15. Recent price targets range from $400.00 to $1500.00.What companies are similar to VXRT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare VXRT side-by-side with any of them on Quantisnow.How can I track VXRT on Quantisnow?
Quantisnow aggregates Vaxart Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VXRT to receive live email and push alerts on every new disclosure.